| Nov 19 |
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
|
| Nov 18 |
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
|
| Nov 18 |
Needham downgrades Biogen on slow growth of Alzheimer's drug
|
| Nov 18 |
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
|
| Nov 18 |
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
|
| Nov 18 |
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
|
| Nov 15 |
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
|
| Nov 14 |
European committee takes a second look at Alzheimer's drug and now says it should be approved
|
| Nov 14 |
5 Healthcare Stocks to Buy in a Beaten-Up Sector
|
| Nov 14 |
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
|
